Smoking Reduction In Gravid Substance Use Disorders
Key facts
- Who runs it
- University of Alabama at Birmingham
- Where
- Birmingham, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 74 people enrolled
- Started
- 15 Feb 2021
- Ended
- 1 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- knowledge of expired maternal carbon monoxide and fetal carboxyhemoglobin levels
- Record updated
- 5 August 2024
Who can take part
- Age
- 16 years to 45 years
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age 16-45
- Singleton gestation
- Gestational age at enrollment <24 weeks
- Substance use disorder defined as modified National Institute on Drug Abuse ASSIST ≥4
- Cigarette smoker using ≥10 cigarettes/day interested in quitting
Who cannot take part
- Known or suspected fetal growth restriction at enrollment
- Known fetal anomaly, aneuploidy, or demise
- Not interested in smoking cessation or reduction during pregnancy
- E-cigarette use
Where in United States
- University of AlabamaBirmingham, United States
About the trial
What the trial wants to find out
The aim of this study is to encourage smoking cessation in women with substance use disorders by providing knowledge of expired carbon monoxide. We hypothesize that women who are provided knowledge of their expired carbon monoxide and the associated percent fetal carboxyhemoglobin will have a greater success at quitting smoking during pregnancy than women who are not provided this information.
Read full original descriptionShow less
A secondary aim of the study is to correlate expired carbon monoxide throughout pregnancy with infant birth weight.
The 2 groups in the trial
- Treatment GroupTreatment being tested
1. The patient will exhaled into the Smokerlyzer® device will at each visit 2. Exhaled carbon monoxide and fetal carboxyhemoglobin levels will be disclosed to the patient 3. Risks of adverse perinatal outcomes related to maternal carboxyhemoglobin and fetal carboxyhemoglobin level will be provided.
Treatment: knowledge of expired maternal carbon monoxide and fetal carboxyhemoglobin levels
- Control GroupNo study treatment, for comparison
1. The patient will exhale into the Smokerlyzer® device at each visit. 2. Exhaled carbon monoxide and fetal carboxyhemoglobin level will NOT be disclosed to the patient 3. No risks of adverse perinatal outcomes related to maternal carbon monoxide and fetal carboxyhemoglobin levels will be provided
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Smoking Reduction In Gravid Women With Substance Use Disorders (SIGS): A Randomized Controlled Trial
- Record updated
- 5 August 2024